Trials / Completed
CompletedNCT05894499
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Cohort Survey on Shock and Anaphylaxis in Persons With Underlying Diseases Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13,309 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19 and explore risk factors.
Detailed description
Data collected from the JDMC Claims Database between May 2021 to November 2021.
Conditions
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
- First posted
- 2023-06-08
- Last updated
- 2024-03-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05894499. Inclusion in this directory is not an endorsement.